- Home
- TDG vs BMY Comparison
TDG vs BMY Comparison
Compare TDG & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDG | BMY |
|---|---|---|
| Founded | 1993 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.9B | 110.2B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | TDG | BMY |
|---|---|---|
| Price | $1,455.30 | $55.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $1,590.77 | $57.64 |
| AVG Volume (30 Days) | 324.5K | ★ 14.2M |
| Earning Date | 02-03-2026 | 02-05-2026 |
| Dividend Yield | ★ 6.21% | 4.56% |
| EPS Growth | ★ 25.13 | N/A |
| EPS | ★ 32.06 | 2.97 |
| Revenue | $8,831,000,000.00 | ★ $48,034,000,000.00 |
| Revenue This Year | $13.63 | $0.28 |
| Revenue Next Year | $8.11 | N/A |
| P/E Ratio | $45.23 | ★ $18.60 |
| Revenue Growth | ★ 11.22 | 1.26 |
| 52 Week Low | $1,183.60 | $42.52 |
| 52 Week High | $1,623.83 | $63.33 |
Technical Indicators
Market Signals| Indicator | TDG | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 77.15 | 56.72 |
| Support Level | $1,374.48 | $55.51 |
| Resistance Level | $1,399.50 | $57.04 |
| Average True Range (ATR) | 27.89 | 1.10 |
| MACD | 10.64 | -0.09 |
| Stochastic Oscillator | 93.49 | 64.06 |
Price Performance
Historical ComparisonAbout TDG Transdigm Group Incorporated
TransDigm manufactures and services a broad set of specialized parts for commercial and military aircraft. The firm organizes itself in three segments: power and control, airframes, and a small non-aviation segment, which serves mostly off-road vehicles and mining equipment. It operates as an acquisitive holding company that focuses its portfolio on firms that make proprietary aerospace products with substantial aftermarket demand. TransDigm regularly employs financial leverage to amplify its operating results.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.